# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k101853   
B. Purpose for Submission: Modified formulation of previously cleared device k07259   
C. Measurand: Lp-PLA2 (lipoprotein-associated phospholipase A2)   
D. Type of Test: Quantitative turbidimetric immunoassay   
E. Applicant: diaDexus   
F. Proprietary and Established Names: PLAC $^ \mathrm { \textregistered }$ Test Reagent Kit   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>NOE</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.5600</td><td rowspan=1 colspan=1>82 Immunology</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indications for use below.

2. Indication(s) for use:

The $\mathrm { P L A C } @$ Test Reagent Kit is a turbidimetric immunoassay for the quantitative determination of Lp-PLA2 (lipoprotein-associated phospholipase A2) in human serum or plasma on automated clinical chemistry analyzers, to be used in

conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk for coronary heart disease, and ischemic stroke associated with atherosclerosis.

3. Special conditions for use statement(s): For prescription use

4. Special instrument requirements: The PLAC $^ \mathrm { \textregistered }$ Test was validated on the Hitach $^ \mathrm { \textregistered }$ 917.

# I. Device Description:

The diaDexus $\mathrm { P L A C } @$ Test assay consists of separately packaged reagents, calibrators and controls for the measurement of Lp- $\mathrm { \bf { P L A } } _ { 2 }$ in serum or plasma. The $\mathrm { P L A C } @$ Test Kit consists of two reagents. R1 is a buffer solution with protein stabilizers and R2 is a suspension of polymeric microparticles coated with mouse monoclonal antibodies specific to Lp-PLA2 (2C10 and 4B4).

# J. Substantial Equivalence Information:

1. Predicate device name(s): diaDexus, PLAC Test ELISA Kit

2. Predicate K number(s): k062234

3. Comparison with predicate:

# Similarities and Differences to the Predicate

# Similarities

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Predicate - k062234 PLAC Test ELISA Kit</td><td rowspan=1 colspan=1>Modified -PLAC TestReagent Kit</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indications foruse</td><td rowspan=1 colspan=1>For the quantitative determination of Lp-PLA2 (lipoprotein-associated phospholipase A2) in human plasma and serum, to be usedin conjunction with clinical evaluation and patient risk assessment asan aid in predicting risk for coronary heart disease, and ischemicstroke associated with atherosclerosis.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Key ReagentComponents</td><td rowspan=1 colspan=1>Anti-PLA2 (2C10) and anti-PLA2 (4B4)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CalibratorsMatrix</td><td rowspan=1 colspan=1>Recombinant Lp-PLA2 antigen in a protein stabilizing diluent</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Control Matrix</td><td rowspan=1 colspan=1>Recombinant Lp-PLA2 antigen in a protein stabilizing diluent</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Controls Levels</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Differences

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Predicate - k062234 PLAC ELISA Kit</td><td rowspan=1 colspan=1>Modified - PLAC Test Reagent Kit</td></tr><tr><td rowspan=1 colspan=1>Measuring range</td><td rowspan=1 colspan=1>Up to 1000 ng/mL</td><td rowspan=1 colspan=1>25 to 500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Dual monoclonal antibody sandwichELISA read at 450 nm on a microwellplate reader</td><td rowspan=1 colspan=1>Immuno- Turbidimetric assay read at570 nm on clinical chemistry analyzers</td></tr><tr><td rowspan=1 colspan=1>ReagentConfiguration</td><td rowspan=1 colspan=1>Anti-Lp-PLA2 mAb (2C10) coatedstripwellsWash bufferEnzyme conjugate anti-Lp-PLA2 mAb(4B4)-HRPTMB substrateStop solution</td><td rowspan=1 colspan=1>Two reagent systemR1- Buffer solution with proteinstabilizersR2- antibody coated microparticles(mAbs 2C10 and 4B4)</td></tr><tr><td rowspan=1 colspan=1>KitConfiguration</td><td rowspan=1 colspan=1>Reagent, calibrators and controls all in onekit</td><td rowspan=1 colspan=1>Reagent, calibrators and controls inseparate kits.</td></tr><tr><td rowspan=1 colspan=1>Calibrator Levels</td><td rowspan=1 colspan=1>6 levels - 0,50,100, 250, 500, 1000 ng/mL</td><td rowspan=1 colspan=1>5 levels - 0, 50, 100, 250, 500 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Samples Types</td><td rowspan=1 colspan=1>Serum, EDTA, Heparin</td><td rowspan=1 colspan=1>Serum, K2EDTA</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI Documents: How to Define Reference Ranges; Approved Guideline (C28 A3).

Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline (EP5-A2)

Evaluation of the Linearity of Quantitative Measurement of Procedures; Approved Guideline (EP6-A)

Interference Testing in Clinical Chemistry; Approved Guideline (EP7-A2)

Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline (EP9 – A2)

Protocols for Determination of LOQ and LOD; Approved Guideline (EP17-A)

Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline (EP25A)

# L. Test Principle:

The PLAC Test Reagent Kit is a turbidimetric immunoassay (TIA) using two specific monoclonal antibodies (2C10 and 4B4) coated to polymeric microparticles in suspension. As the concentration of Lp- $\mathrm { \bf P } \mathrm { \bf L A } _ { 2 }$ increases, the turbidity of the suspension also increases, and this change in absorbance is read at $5 7 0 \mathrm { n m }$ on a clinical chemistry analyzer. The change in absorbance is proportional to the amount of Lp- $\mathrm { P L A } _ { 2 }$ in the patient sample. A set of Lp- $\mathrm { P L A } _ { 2 }$ calibrators is used to plot a standard curve of absorbance (y-axis) versus Lp- $\mathrm { \mathrm { P L A } } _ { 2 }$ concentration in $\mathrm { { n g / m L } }$ (x

axis) from which the $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ sample concentration can be determined by interpolation from the standard curve.

# M. Performance Characteristics (if/when applicable):

The PLAC Test was validated on the Hitachi $^ \mathrm { \textregistered }$ 917

1. Analytical performance:

a. Precision/Reproducibility:

Intra-assay, inter-assay and total precision was assessed according to CLSI EP5 – A2 with three reagent lots. Two buffered controls and five serum samples (values ranging from 51 to $4 4 9 \mathrm { n g / m L }$ ) were assayed in duplicates in 2 separate runs on the Hitachi 917 analyzer for 20 days. The results are shown in the table below:

<table><tr><td colspan="1" rowspan="1">ReagentLot</td><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Mean Lp-PLA Conc.2(ng/mL)</td><td colspan="1" rowspan="1">Intra-assay %CVn=40</td><td colspan="1" rowspan="1">Inter-assay%CV n=40</td><td colspan="1" rowspan="1">Total %CVn=80</td></tr><tr><td colspan="1" rowspan="7">1</td><td colspan="1" rowspan="1">SerumSample 1</td><td colspan="1" rowspan="1">56.2</td><td colspan="1" rowspan="1">2.50%</td><td colspan="1" rowspan="1">4.60%</td><td colspan="1" rowspan="1">5.30%</td></tr><tr><td colspan="1" rowspan="1">SerumSample 2</td><td colspan="1" rowspan="1">108.9</td><td colspan="1" rowspan="1">1.30%</td><td colspan="1" rowspan="1">3.00%</td><td colspan="1" rowspan="1">3.30%</td></tr><tr><td colspan="1" rowspan="1">LowBufferControl</td><td colspan="1" rowspan="1">191.2</td><td colspan="1" rowspan="1">0.70%</td><td colspan="1" rowspan="1">0.90%</td><td colspan="1" rowspan="1">1.40%</td></tr><tr><td colspan="1" rowspan="1">SerumSample 3</td><td colspan="1" rowspan="1">250.1</td><td colspan="1" rowspan="1">1.00%</td><td colspan="1" rowspan="1">2.70%</td><td colspan="1" rowspan="1">2.90%</td></tr><tr><td colspan="1" rowspan="1">SerumSample 4</td><td colspan="1" rowspan="1">275.6</td><td colspan="1" rowspan="1">0.90%</td><td colspan="1" rowspan="1">2.60%</td><td colspan="1" rowspan="1">2.70%</td></tr><tr><td colspan="1" rowspan="1">HighBufferControl</td><td colspan="1" rowspan="1">370.8</td><td colspan="1" rowspan="1">1.00%</td><td colspan="1" rowspan="1">0.70%</td><td colspan="1" rowspan="1">1.60%</td></tr><tr><td colspan="1" rowspan="1">SerumSample 5</td><td colspan="1" rowspan="1">439.1</td><td colspan="1" rowspan="1">1.70%</td><td colspan="1" rowspan="1">2.90%</td><td colspan="1" rowspan="1">3.30%</td></tr><tr><td colspan="1" rowspan="6">2</td><td colspan="1" rowspan="1">SerumSample 1</td><td colspan="1" rowspan="1">55.4</td><td colspan="1" rowspan="1">2.10%</td><td colspan="1" rowspan="1">5.40%</td><td colspan="1" rowspan="1">5.80%</td></tr><tr><td colspan="1" rowspan="1">SerumSample 2</td><td colspan="1" rowspan="1">108.2</td><td colspan="1" rowspan="1">1.60%</td><td colspan="1" rowspan="1">2.50%</td><td colspan="1" rowspan="1">3.00%</td></tr><tr><td colspan="1" rowspan="1">LowBufferControl</td><td colspan="1" rowspan="1">189.2</td><td colspan="1" rowspan="1">0.70%</td><td colspan="1" rowspan="1">0.80%</td><td colspan="1" rowspan="1">1.50%</td></tr><tr><td colspan="1" rowspan="1">SerumSample 3</td><td colspan="1" rowspan="1">235.4</td><td colspan="1" rowspan="1">1.40%</td><td colspan="1" rowspan="1">1.90%</td><td colspan="1" rowspan="1">2.30%</td></tr><tr><td colspan="1" rowspan="1">SerumSample 4</td><td colspan="1" rowspan="1">275</td><td colspan="1" rowspan="1">1.00%</td><td colspan="1" rowspan="1">1.50%</td><td colspan="1" rowspan="1">1.80%</td></tr><tr><td colspan="1" rowspan="1">HighBufferControl</td><td colspan="1" rowspan="1">367.8</td><td colspan="1" rowspan="1">0.90%</td><td colspan="1" rowspan="1">1.20%</td><td colspan="1" rowspan="1">1.50%</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">SerumSample 5</td><td colspan="1" rowspan="1">449.1</td><td colspan="1" rowspan="1">1.40%</td><td colspan="1" rowspan="1">2.00%</td><td colspan="1" rowspan="1">2.40%</td></tr><tr><td colspan="1" rowspan="7">3</td><td colspan="1" rowspan="1">SerumSample 1</td><td colspan="1" rowspan="1">51.1</td><td colspan="1" rowspan="1">2.10%</td><td colspan="1" rowspan="1">5.30%</td><td colspan="1" rowspan="1">5.70%</td></tr><tr><td colspan="1" rowspan="1">SerumSample 2</td><td colspan="1" rowspan="1">101.3</td><td colspan="1" rowspan="1">1.40%</td><td colspan="1" rowspan="1">3.50%</td><td colspan="1" rowspan="1">3.70%</td></tr><tr><td colspan="1" rowspan="1">LowBufferControl</td><td colspan="1" rowspan="1">190.8</td><td colspan="1" rowspan="1">0.90%</td><td colspan="1" rowspan="1">1.00%</td><td colspan="1" rowspan="1">1.40%</td></tr><tr><td colspan="1" rowspan="1">SerumSample 3</td><td colspan="1" rowspan="1">227.6</td><td colspan="1" rowspan="1">0.80%</td><td colspan="1" rowspan="1">2.50%</td><td colspan="1" rowspan="1">2.80%</td></tr><tr><td colspan="1" rowspan="1">SerumSample 4</td><td colspan="1" rowspan="1">256.8</td><td colspan="1" rowspan="1">0.90%</td><td colspan="1" rowspan="1">2.50%</td><td colspan="1" rowspan="1">2.80%</td></tr><tr><td colspan="1" rowspan="1">HighBuferControl</td><td colspan="1" rowspan="1">372.1</td><td colspan="1" rowspan="1">0.80%</td><td colspan="1" rowspan="1">1.10%</td><td colspan="1" rowspan="1">1.60%</td></tr><tr><td colspan="1" rowspan="1">SerumSample 5</td><td colspan="1" rowspan="1">416</td><td colspan="1" rowspan="1">1.70%</td><td colspan="1" rowspan="1">2.90%</td><td colspan="1" rowspan="1">3.40%</td></tr></table>

# $b$ . Linearity/assay reportable range:

The recovery of the reportable range was assessed according to CLSI EP6-A. Ten sample sets were prepared using 3 sets of low and high serum samples and 7 sets prepared using a high serum sample and bovine calf serum (negative serum source). The samples were assayed in duplicates with 3 lots on a single analyzer. Percent recovery was determined and linear regression analysis was conducted. The results are presented in the table below. The linear range was determined as $2 5 { - } 5 0 0 ~ \mathrm { n g / m L }$ .

Lot 1 Results:   

<table><tr><td colspan="1" rowspan="2">Serum SamplesUsed</td><td colspan="1" rowspan="2">HighSample(ng/mL)</td><td colspan="1" rowspan="2">LowSample(ng/mL)</td><td colspan="1" rowspan="2">Mean %Recovery</td><td colspan="3" rowspan="1">Linear RegressionParameters</td></tr><tr><td colspan="1" rowspan="1">Slope</td><td colspan="1" rowspan="1">Intercept</td><td colspan="1" rowspan="1">R^{}$</td></tr><tr><td colspan="1" rowspan="1">Pair 1 HumanHigh, HumanLow</td><td colspan="1" rowspan="1">509</td><td colspan="1" rowspan="1">63</td><td colspan="1" rowspan="1">102%</td><td colspan="1" rowspan="1">0.994</td><td colspan="1" rowspan="1">6.3988</td><td colspan="1" rowspan="1">0.9992</td></tr><tr><td colspan="1" rowspan="1">Pair 2 HumanHigh, HumanLow</td><td colspan="1" rowspan="1">527</td><td colspan="1" rowspan="1">63</td><td colspan="1" rowspan="1">99%</td><td colspan="1" rowspan="1">0.997</td><td colspan="1" rowspan="1">-1.5402</td><td colspan="1" rowspan="1">0.9988</td></tr><tr><td colspan="1" rowspan="1">Pair 3 HumanHigh, HumanLow</td><td colspan="1" rowspan="1">493</td><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">104%</td><td colspan="1" rowspan="1">1.0027</td><td colspan="1" rowspan="1">8.1817</td><td colspan="1" rowspan="1">0.9986</td></tr><tr><td colspan="1" rowspan="1">Pair 4 HumanHigh, BCS Low;50 ng</td><td colspan="1" rowspan="1">504</td><td colspan="1" rowspan="1">58</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">0.9979</td><td colspan="1" rowspan="1">5.0396</td><td colspan="1" rowspan="1">0.9994</td></tr><tr><td colspan="1" rowspan="1">Pair 5 HumanHigh, BCS Low;"50 ng</td><td colspan="1" rowspan="1">503</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">102%</td><td colspan="1" rowspan="1">0.9764</td><td colspan="1" rowspan="1">9.4004</td><td colspan="1" rowspan="1">0.9987</td></tr><tr><td colspan="1" rowspan="1">Pair 6 HumanHigh, BCS Low;50 ng</td><td colspan="1" rowspan="1">459</td><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">102%</td><td colspan="1" rowspan="1">0.988</td><td colspan="1" rowspan="1">5.8214</td><td colspan="1" rowspan="1">0.9996</td></tr><tr><td colspan="1" rowspan="1">Pair 7 Human</td><td colspan="1" rowspan="1">545</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">0.9759</td><td colspan="1" rowspan="1">4.2625</td><td colspan="1" rowspan="1">0.999</td></tr><tr><td colspan="1" rowspan="3">Serum SamplesUsedHigh, BCS Low;50 ng</td><td colspan="1" rowspan="3">HighSample(ng/mL)</td><td colspan="1" rowspan="3">LowSample(ng/mL)</td><td colspan="1" rowspan="3">Mean %Recovery</td><td colspan="3" rowspan="1">Linear RegressionParameters</td></tr><tr><td colspan="1" rowspan="1">Slope</td><td colspan="1" rowspan="1">Intercept</td><td colspan="1" rowspan="1">R^{}$</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Pair 8 HumanHigh, BCS Low;25 ng</td><td colspan="1" rowspan="1">503</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">103%</td><td colspan="1" rowspan="1">0.9852</td><td colspan="1" rowspan="1">6.9042</td><td colspan="1" rowspan="1">0.999</td></tr><tr><td colspan="1" rowspan="1">Pair 9 HumanHigh, BCS Low;25 ng</td><td colspan="1" rowspan="1">459</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">102%</td><td colspan="1" rowspan="1">0.9932</td><td colspan="1" rowspan="1">4.9752</td><td colspan="1" rowspan="1">0.9996</td></tr><tr><td colspan="1" rowspan="1">Pair 10 HumanHigh, BCS Low;25 ng</td><td colspan="1" rowspan="1">545</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">101%</td><td colspan="1" rowspan="1">0.9779</td><td colspan="1" rowspan="1">4.6619</td><td colspan="1" rowspan="1">0.9991</td></tr></table>

Lot 2 Results:   

<table><tr><td rowspan=2 colspan=1>Serum SamplesUsed</td><td rowspan=2 colspan=1>HighSample(ng/mL)</td><td rowspan=2 colspan=1>LowSample(ng/mL)</td><td rowspan=2 colspan=1>Mean %Recovery</td><td rowspan=1 colspan=3>Linear RegressionParameters</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R{}$</td></tr><tr><td rowspan=1 colspan=1>Pair 1 HumanHigh, HumanLow</td><td rowspan=1 colspan=1>517</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>0.9785</td><td rowspan=1 colspan=1>6.2799</td><td rowspan=1 colspan=1>0.9978</td></tr><tr><td rowspan=1 colspan=1>Pair 2 HumanHigh, HumanLow</td><td rowspan=1 colspan=1>523</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0.9942</td><td rowspan=1 colspan=1>12.823</td><td rowspan=1 colspan=1>0.9979</td></tr><tr><td rowspan=1 colspan=1>Pair 3 HumanHigh, HumanLow</td><td rowspan=1 colspan=1>515</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>1.0176</td><td rowspan=1 colspan=1>4.0659</td><td rowspan=1 colspan=1>0.9977</td></tr><tr><td rowspan=1 colspan=1>Pair 4 HumanHigh, BCS Low;50 ng</td><td rowspan=1 colspan=1>519</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>0.9898</td><td rowspan=1 colspan=1>6.528</td><td rowspan=1 colspan=1>0.9992</td></tr><tr><td rowspan=1 colspan=1>Pair 5 HumanHigh, BCS Low;50 ng</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>0.9925</td><td rowspan=1 colspan=1>5.8824</td><td rowspan=1 colspan=1>0.9987</td></tr><tr><td rowspan=1 colspan=1>Pair 6 HumanHigh, BCS Low;50 ng</td><td rowspan=1 colspan=1>465</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>0.9962</td><td rowspan=1 colspan=1>5.0256</td><td rowspan=1 colspan=1>0.9995</td></tr><tr><td rowspan=1 colspan=1>Pair 7 HumanHigh, BCS Low;50 ng</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>101%</td><td rowspan=1 colspan=1>0.9847</td><td rowspan=1 colspan=1>5.6655</td><td rowspan=1 colspan=1>0.9993</td></tr><tr><td rowspan=1 colspan=1>Pair 8 HumanHigh, BCS Low;25 ng</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>104%</td><td rowspan=1 colspan=1>0.9951</td><td rowspan=1 colspan=1>6.4466</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>Pair 9 HumanHigh, BCS Low;25 ng</td><td rowspan=1 colspan=1>465</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>103%</td><td rowspan=1 colspan=1>1.0017</td><td rowspan=1 colspan=1>3.7621</td><td rowspan=1 colspan=1>0.9996</td></tr><tr><td rowspan=1 colspan=1>Pair 10 HumanHigh, BCS Low;25 ng</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>101%</td><td rowspan=1 colspan=1>0.9907</td><td rowspan=1 colspan=1>3.8576</td><td rowspan=1 colspan=1>0.9993</td></tr></table>

Lot 3 Results:   

<table><tr><td rowspan=2 colspan=1>Serum SamplesUsed</td><td rowspan=2 colspan=1>HighSample(ng/mL)</td><td rowspan=2 colspan=1>Lowample(n/mL)</td><td rowspan=2 colspan=1>Mean %Recovery</td><td rowspan=1 colspan=3>Linear RegressionParameters</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R2</td></tr><tr><td rowspan=1 colspan=1>Pair 1 HumanHigh, HumanLow</td><td rowspan=1 colspan=1>486</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>103%</td><td rowspan=1 colspan=1>1.0076</td><td rowspan=1 colspan=1>5.7815</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>Pair 2 HumanHigh, HumanLow</td><td rowspan=1 colspan=1>497</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>101%</td><td rowspan=1 colspan=1>1.0031</td><td rowspan=1 colspan=1>0.7276</td><td rowspan=1 colspan=1>0.9998</td></tr><tr><td rowspan=1 colspan=1>Pair 3 HumanHigh, HumanLow</td><td rowspan=1 colspan=1>472</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>103%</td><td rowspan=1 colspan=1>1.0018</td><td rowspan=1 colspan=1>6.4618</td><td rowspan=1 colspan=1>0.9991</td></tr><tr><td rowspan=1 colspan=1>Pair 4 HumanHigh, BCS Low;50 ng</td><td rowspan=1 colspan=1>486</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>103%</td><td rowspan=1 colspan=1>0.999</td><td rowspan=1 colspan=1>7.3023</td><td rowspan=1 colspan=1>0.9992</td></tr><tr><td rowspan=1 colspan=1>Pair 5 HumanHigh, BCS Low;50 ng</td><td rowspan=1 colspan=1>475</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>104%</td><td rowspan=1 colspan=1>0.9938</td><td rowspan=1 colspan=1>9.1189</td><td rowspan=1 colspan=1>0.9988</td></tr><tr><td rowspan=1 colspan=1>Pair 6 HumanHigh, BCS Low;50 ng</td><td rowspan=1 colspan=1>436</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>1.0053</td><td rowspan=1 colspan=1>3.6708</td><td rowspan=1 colspan=1>0.9995</td></tr><tr><td rowspan=1 colspan=1>Pair 7 HumanHigh, BCS Low;50 ng</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>0.9913</td><td rowspan=1 colspan=1>5.356</td><td rowspan=1 colspan=1>0.9995</td></tr><tr><td rowspan=1 colspan=1>Pair 8 HumanHigh, BCS Low;25 ng</td><td rowspan=1 colspan=1>475</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>104%</td><td rowspan=1 colspan=1>1.0044</td><td rowspan=1 colspan=1>5.8435</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>Pair 9 HumanHigh, BCS Low;25 ng</td><td rowspan=1 colspan=1>436</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>1.0114</td><td rowspan=1 colspan=1>2.0716</td><td rowspan=1 colspan=1>0.9995</td></tr><tr><td rowspan=1 colspan=1>Pair 10 HumanHigh, BCS Low;25 ng</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>102%</td><td rowspan=1 colspan=1>0.9973</td><td rowspan=1 colspan=1>3.7246</td><td rowspan=1 colspan=1>0.9995</td></tr></table>

Additionally, the zero calibrator was spiked with varying levels of recombinant Lp- $\mathrm { P L A } _ { 2 }$ up to $3 , 0 0 0 ~ \mathrm { n g / m L }$ and tested to assess the prozone or high hook dose effect. The results of the hook effect study supports the sponsor’s claimed measuring range of $2 5 { - } 5 0 0 ~ \mathrm { n g / m L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The PLAC Test Calibrator Kit and Lp- $\mathrm { \mathrm { . P L A } } _ { 2 }$ Control Kit were previously cleared and have not been modified, see k072599 for traceability, stability, and expected values.

Shelf life stability testing was performed on 3 reagent lots stored capped at $3 7 \mathrm { { ^ \circ C } }$ which was compared to the established PLAC Test Reagent Kit (k072599) also stored at $3 7 \mathrm { { ^ \circ C } }$ . Each reagent was calibrated at each time point before testing samples. Each sample was tested at days 1,6,8,15,21, and 42 with two replicates per sample. Two buffer based controls and 5 serum samples ranging from $5 5 { - } 4 5 5 ~ \mathrm { n g / m L }$ were assayed. The reagent fill volumes for each reagent kit were equivalent to a 100 test fill volume. The control reagent met the acceptance criteria. Real-time stability study is on going.

On-board stability testing of the reagent was performed with the reagent stored uncapped on-board the Hitachi $^ \mathrm { \textregistered }$ 917 analyzer. One lot of reagent was tested for on-board stability. Two controls and 5 human samples ranging from 58 to $4 4 8 ~ \mathrm { { n g / m L } }$ were run once a week for three weeks with a calibration performed at time 0. Five replicates were run for each sample. The results met the acceptance criteria with $90 \mathrm { - } 1 1 0 \%$ average recovery from time 0 for at least 2 weeks. This supports the claimed on-board stability claim of 2 weeks.

# d. Detection limit:

The sponsor conducted a Limit of Blank (LoB), Limit of Detection (LoD) and a Limit of Quantitation (LoQ) study. The detection limit was defined as the lowest quantity of $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ that is significantly different from the absence of any $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ . In order to determine the LoD, the LoB was first defined by running 60 replicates of the 0 level calibrator using three reagent lots. Then, six low serum samples were prepared by diluting serum samples with fetal bovine serum $\left( \mathrm { L p } { \cdot } \mathrm { P L A } _ { 2 } \right.$ negative serum). Each sample was tested in duplicate over 5 days (10 results per sample, $\scriptstyle \mathrm { n = 6 0 }$ ).

The results of the LoB and LoD studies are summarized in the following table:   

<table><tr><td rowspan=1 colspan=1>Lot</td><td rowspan=1 colspan=1>LoB (ng/mL)</td><td rowspan=1 colspan=1>LoD (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1.99</td><td rowspan=1 colspan=1>4.50</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3.17</td><td rowspan=1 colspan=1>5.84</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1.65</td><td rowspan=1 colspan=1>4.15</td></tr></table>

The LOQ was defined as the lowest concentration at which an analyte can be measured accurately without exceeding $20 \%$ CV. Three low serum samples were diluted with fetal bovine serum in a series of four dilutions per sample $( 1 \mathrm { x } , 0 . 5 \mathrm { x } , 0 . 2 5 \mathrm { x }$ , and 0.125x). Each sample was tested in duplicate in 10 runs by three reagent lots on one analyzer. The sponsor’s predetermined total error goal was $\leq 5 ~ \mathrm { { n g / m L } }$ for $\mathrm { L o Q } \leq 2 0 \mathrm { n g / m L }$ . The total error estimate was $\leq 5$ $\mathrm { { n g / m L } }$ for all three lots, therefore, LoQ=LoD (4.5, 5.8, $4 . 2 \ : \mathrm { n g / m L }$ ).

The measuring range of the assay was established as $2 5 - 5 0 0 ~ \mathrm { n g / m L }$ based on the linearity studies and detection limit studies.

# e. Analytical specificity:

Five endogenous substances (hemoglobin, triglycerides, total cholesterol, bilirubin, and human serum albumin) and exogenous substances (common and prescription drugs in the package insert) were evaluated for interference in the assay. Potential interfering substances were spiked with interferent into four different serum samples with endogenous $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ ranging from 140-500 $\mathrm { n g / m L }$ . Defined amounts of the interferents at and exceeding a relevant physiological range were added to the serum samples, assayed in duplicate with three lots of reagents. Interferent test concentrations were selected according to CLSI Protocol EP7-A2. Controls were prepared for each sample by spiking with solvent used for each substance stock solution. Controls were matched to test samples for volume and solvent concentration. Recoveries of test samples were calculated as result/matched control value $\textbf { x l } 0 0 \%$ . Testing results met the sponsor’s acceptance criteria of less than $10 \%$ error in detected $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ in the presence of the compound. There was no significant (less than or equal to $10 \%$ ) interference detected for any of the substances listed below.

<table><tr><td rowspan=1 colspan=2>Endogenous Substances</td></tr><tr><td rowspan=1 colspan=1>Potential Interferent</td><td rowspan=1 colspan=1>Test Concentration</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>3,000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>5,000 mg/dL</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Exogenous (OTC Drugs, etc.)</td></tr><tr><td rowspan=1 colspan=1>Potential Interferent</td><td rowspan=1 colspan=1>Test Concentration</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>1654 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Aspirin</td><td rowspan=1 colspan=1>3620 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Atorvastatin</td><td rowspan=1 colspan=1>20 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Clopidogrel bisulfate</td><td rowspan=1 colspan=1>100 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Diphenhydramine</td><td rowspan=1 colspan=1>19.6 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Fenofibrate</td><td rowspan=1 colspan=1>125μmol/L</td></tr><tr><td rowspan=1 colspan=1>Lisinopril</td><td rowspan=1 colspan=1>0.74 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Metformin</td><td rowspan=1 colspan=1>310 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Niacin</td><td rowspan=1 colspan=1>4804 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Tolbutamide</td><td rowspan=1 colspan=1>2370 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Vitamin C</td><td rowspan=1 colspan=1>227 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Warfarin</td><td rowspan=1 colspan=1>64.9 μmol/L</td></tr></table>

f. Assay cut-off: Not applicable.

2. Comparison studies: a. Method comparison with predicate device:

The current PLAC Test turbidimetric immunoassay method testing 3 lots on the Hitachi 917 was compared to the PLAC Test ELISA microplate assay (k062234). The singlet point method comparison for the 742 unaltered stored human serum samples ranged from $2 5 { - } 5 0 0 ~ \mathrm { n g / m L }$ , obtained from banked study sets were within the sponsor’s linear range. The results are shown in the table below.

Method Comparisons of PLAC Test Reagent Kit Lots vs. ELISA (Lots 1, 2 and 3)   

<table><tr><td rowspan=1 colspan=1>PLAC Test ReagentKit Lots</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1># samples</td></tr><tr><td rowspan=1 colspan=1>Lot 1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>742</td></tr><tr><td rowspan=1 colspan=1>Lot 2</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>-2.9</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>742</td></tr><tr><td rowspan=1 colspan=1>Lot 3</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>-2.2</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>742</td></tr></table>

# b. Matrix comparison:

The sponsor conducted a matrix comparison study with the PLAC turbidimetric immunoassay. Twenty fresh samples were collected in each of the four tube types (Serum with separator (SST), Serum, EDTA Plasma, and EDTA Plasma with separator) and an aliquot of each sample was stored at $4 \%$ and $- 7 0 \mathrm { { \circ C } }$ for 1 day post collection. An additional twenty banked and paired SST/K2EDTA samples obtained from a commercial sample bank were used to cover the upper assay range. These samples were stored at $- 7 0 \mathrm { { } ^ { \circ } C }$ until use. Each sample was tested in triplicate using one lot of reagent on a single Hitachi 917 analyzer. Samples tested ranged from 59 to $4 1 8 ~ \mathrm { { n g / m L } }$ . The resulting recoveries ranged from $9 5 \%$ to $1 1 0 \%$ . The results of the regression analyses are shown in the table below.

<table><tr><td rowspan=1 colspan=4>Regression Parameters</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Correl. Coeff(r)</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td></tr><tr><td rowspan=1 colspan=1>Serum vs. SST</td><td rowspan=1 colspan=1>0.9980</td><td rowspan=1 colspan=1>0.9998</td><td rowspan=1 colspan=1>0.0097</td></tr><tr><td rowspan=1 colspan=1>Plasma gel vs.SST</td><td rowspan=1 colspan=1>0.9837</td><td rowspan=1 colspan=1>0.9460</td><td rowspan=1 colspan=1>-1.747</td></tr><tr><td rowspan=1 colspan=1>Plasma vs. SST</td><td rowspan=1 colspan=1>0.9931</td><td rowspan=1 colspan=1>0.9048</td><td rowspan=1 colspan=1>2.968</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): See clinical data provided in k030477. Also see method comparison in 2. a. above and the reference range study presented in 5. below.

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

A screened normal healthy population who met the following inclusion criteria for the study: not on any lipid-modifying medications and have no reported evidence of cardiovascular disease. In addition, the following exclusion criteria were utilized: age ${ < } 3 5$ , currently on lipid-modifying medications, and with a reported history of cardiovascular disease. The sponsor collected a set of 312 screened samples from a clinical research organization. Samples were of men and women between the ages of 35-75 years old (median age of 50 years).

The demographics are as followed:   

<table><tr><td rowspan=1 colspan=1>Population</td><td rowspan=1 colspan=1>Number</td><td rowspan=1 colspan=1>AgeMedian (Range)</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>312</td><td rowspan=1 colspan=1>50 (35-75)</td></tr><tr><td rowspan=1 colspan=1>Males</td><td rowspan=1 colspan=1>168</td><td rowspan=1 colspan=1>52(35-75)</td></tr><tr><td rowspan=1 colspan=1>Females</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>47 (35-69)</td></tr></table>

The results of this study and the results previously obtained with the predicate device in $\mathrm { k } 0 6 2 2 3 4$ are presented in the following table:

<table><tr><td colspan="4" rowspan="1">Results of Reference Range Study</td><td colspan="3" rowspan="1">Predicate Device -k062234</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">All(n=312)</td><td colspan="1" rowspan="1">Males(n=168)</td><td colspan="1" rowspan="1">Females(n=144)</td><td colspan="1" rowspan="1">All(n=425)</td><td colspan="1" rowspan="1">Females(n=174)</td><td colspan="1" rowspan="1">Males(n=251)</td></tr><tr><td colspan="1" rowspan="1">Percentile</td><td colspan="1" rowspan="1">Lp-PLA2(ng/mL)</td><td colspan="1" rowspan="1">Lp-PLA2(ng/mL)</td><td colspan="1" rowspan="1">Lp-PLA2(ng/mL</td><td colspan="1" rowspan="1">Lp-PLA2(ng/mL)</td><td colspan="1" rowspan="1">Lp-PLA2(ng/mL)</td><td colspan="1" rowspan="1">Lp-PLA2(ng/mL)</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">131</td><td colspan="1" rowspan="1">147</td><td colspan="1" rowspan="1">112</td><td colspan="1" rowspan="1">126</td><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">131</td></tr><tr><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">185</td><td colspan="1" rowspan="1">194</td><td colspan="1" rowspan="1">182</td><td colspan="1" rowspan="1">174</td><td colspan="1" rowspan="1">169</td><td colspan="1" rowspan="1">179</td></tr><tr><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">206</td><td colspan="1" rowspan="1">215</td><td colspan="1" rowspan="1">194</td><td colspan="1" rowspan="1">201</td><td colspan="1" rowspan="1">188</td><td colspan="1" rowspan="1">205</td></tr><tr><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">228</td><td colspan="1" rowspan="1">234</td><td colspan="1" rowspan="1">215</td><td colspan="1" rowspan="1">235</td><td colspan="1" rowspan="1">228</td><td colspan="1" rowspan="1">244</td></tr><tr><td colspan="1" rowspan="1">67</td><td colspan="1" rowspan="1">252</td><td colspan="1" rowspan="1">259</td><td colspan="1" rowspan="1">244</td><td colspan="1" rowspan="1">262</td><td colspan="1" rowspan="1">252</td><td colspan="1" rowspan="1">268</td></tr><tr><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">277</td><td colspan="1" rowspan="1">285</td><td colspan="1" rowspan="1">273</td><td colspan="1" rowspan="1">289</td><td colspan="1" rowspan="1">285</td><td colspan="1" rowspan="1">293</td></tr><tr><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">339</td><td colspan="1" rowspan="1">355</td><td colspan="1" rowspan="1">332</td><td colspan="1" rowspan="1">369</td><td colspan="1" rowspan="1">342</td><td colspan="1" rowspan="1">376</td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.